A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells

Clinical Cancer Research

Volumn 20, Issue 8, 2014, Pages 2126-2135

  Hight, Matthew R ^a,g   Cheung, Yiu Yin ^g   Nickels, Michael L ^g,h   Dawson, Eric S ^b,f   Zhao, Ping ^g   Saleh, Samir ^g   Buck, Jason R ^g,h   Tang, Dewei ^g   Washington, M Kay ^c,j   Coffey, Robert J ^d,j,k,l   Manning, H Charles ^e,g,h,i,j,k  

^a Interdisciplinary Materials Science Program Department of Physics and Astronomy   (United States)

^b Departments of Biochemistry   (United States)

^c Departments of Pathology   (United States)

^d Departments of Cell and Developmental Biology   (United States)

^e Departments of Biomedical Engineering   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h Departments of Radiology and Radiological Sciences   (United States)

ⁱ Departments of Neurosurgery   (United States)

^j VANDERBILT INGRAM CANCER CENTER   (United States)

^k VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 FLUOROBENZYLCARBONYL VALYLALANYL O METHYLASPARTATE FLUOROMETHYLKETONE F 18; BARASERTIB; DACTOLISIB; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2-((3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)(ETHYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE INHIBITOR; FLUORINE; FLUOROBENZENE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ORGANOPHOSPHATE; PEPTIDE; PEPTIDE CHLOROMETHYL KETONE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; SULFONAMIDE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLON CANCER; COLORECTAL CANCER; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MONITORING; DRUG POTENCY; DRUG RESPONSE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; FLUORINATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOPHILICITY; MALE; MOLECULAR IMAGING; MOLECULAR PROBE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CHEMISTRY; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DIAGNOSTIC USE; DRUG EFFECTS; DRUG SCREENING; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; APOPTOSIS; CASPASE 3; CASPASE INHIBITORS; CELL LINE, TUMOR; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; FLUOROBENZENES; HUMANS; IMIDAZOLES; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INDOLES; MICE, INBRED C57BL; MICE, NUDE; ORGANOPHOSPHATES; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; QUINOLINES; RADIOPHARMACEUTICALS; SULFONAMIDES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898956686     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2444     Document Type: Article

References (50)

1. Bosman FT, Visser BC, van Oeveren J. Apoptosis: pathophysiology of programmed cell death. Pathol Res Pract 1996;192:676-83.
2. Duprez L, Wirawan E, Vanden Berghe T, Vandenabeele P. Major cell death pathways at a glance. Microbes Infect 2009;11:1050-62.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
4. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-52.
5. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009;9:501-7.
6. Reshef A, Shirvan A, Akselrod-Ballin A, Wall A, Ziv I. Small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med 2010;51:837-40.
7. Boersma HH, Kietselaer BL, Stolk LM, Bennaghmouch A, Hofstra L, Narula J, et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. J Nucl Med 2005;46: 2035-50.
8. Nguyen QD, Challapalli A, Smith G, Fortt R, Aboagye EO. Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F]ICMT- 11. Eur J Cancer 2012;48:432-40.
9. Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, Shah C, et al. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 2008;14:7413-22.
10. Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, et al. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 2009;15:4712-21.
11. Schutters K, Reutelingsperger C. Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis 2010;15: 1072-82.
12. Blankenberg FG, Vanderheyden JL, Strauss HW, Tait JF. Radiolabeling of HYNIC-annexin V with technetium-99m for in vivo imaging of apoptosis. Nat Protoc 2006;1:108-10.
13. Ke S, Wen X, Wu QP, Wallace S, Charnsangavej C, Stachowiak AM, et al. Imaging taxane-induced tumor apoptosis using PEGylated, 111In-labeled annexin V. J Nucl Med 2004;45:108-15.
14. Yagle KJ, Eary JF, Tait JF, Grierson JR, Link JM, Lewellen B, et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005;46:658-66.
15. Bauwens M, De Saint-Hubert M, Devos E, Deckers N, Reutelingsperger C, Mortelmans L, et al. Site-specific 68Ga-labeled Annexin A5 as a PET imaging agent for apoptosis. Nucl Med Biol 2011;38:381-92.
16. Balasubramanian K, Mirnikjoo B, Schroit AJ. Regulated externalization of phosphatidylserine at the cell surface: implications for apoptosis. J Biol Chem 2007;282:18357-64.
17. Dillon SR, Constantinescu A, Schlissel MS. Annexin V binds to positively selected B cells. J Immunol 2001;166:58-71.
18. Balasubramanian K, Schroit AJ. Aminophospholipid asymmetry: a matter of life and death. Annu Rev Physiol 2003;65:701-34.
19. Elliott JI, Surprenant A, Marelli-Berg FM, Cooper JC, Cassady-Cain RL, Wooding C, et al. Membrane phosphatidylserine distribution as a non-apoptotic signalling mechanism in lymphocytes. Nat Cell Biol 2005;7:808-16.
20. Hoglund J, Shirvan A, Antoni G, Gustavsson SA, Langstrom B, Ringheim A, et al. 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med 2011;52:720-5.
21. Allen AM, Ben-Ami M, Reshef A, Steinmetz A, Kundel Y, Inbar E, et al. Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with (1)(8)F-ML-10. Eur J Nucl Med Mol Imaging 2012;39:1400-8.
22. Blankenberg FG. In vivo detection of apoptosis. J Nucl Med 2008;49 (Suppl 2):81S-95S.
23. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998;273:32608-13.
24. Ekert PG, Silke J, Vaux DL. Caspase inhibitors. Cell Death Differ 1999;6:1081-6.
25. Ganesan R, Jelakovic S, Campbell AJ, Li ZZ, Asgian JL, Powers JC, et al. Exploring the S4 and S1 prime subsite specificities in caspase-3 with aza-peptide epoxide inhibitors. Biochemistry 2006;45:9059-67.
26. Wang Z, Watt W, Brooks NA, Harris MS, Urban J, Boatman D, et al. Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors. Biochim Biophys Acta 2010;1804:1817-31.
27. Waterhouse RN, Mardon K, Giles KM, Collier TL, O'Brien JC. Halogenated 4-(phenoxymethyl)piperidines as potential radiolabeled probes for sigma-1 receptors: in vivo evaluation of [123I]-1-(iodopropen- 2-yl)-4-[(4-cyanophenoxy) methyl]piperidine. J Med Chem 1997; 40:1657-67.
28. Ren YG, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M, Deveraux QL. Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell 2004;15:5064-74.
29. Xu J, Li K, Smith RA, Waterton JC, Zhao P, Chen H, et al. Characterizing tumor response to chemotherapy at various length scales using temporal diffusion spectroscopy. PLoS ONE 2012;7:e41714.
30. Buck JR, Saleh S, Uddin MI, Manning HC. Rapid, microwave-assisted organic synthesis of selective (V600E)BRAF inhibitors for preclinical cancer research. Tetrahedron Lett 2012;53:4161-5.
31. Ayers GD, McKinley ET, Zhao P, Fritz JM, Metry RE, Deal BC, et al. Volume of preclinical xenograft tumors is more accurately assessed by ultrasound imaging than manual caliper measurements. J Ultrasound Med 2010;29:891-901.
32. McKinley ET, Smith RA, Zhao P, Fu A, Saleh SA, Uddin MI, et al. 30- Deoxy-30-18F-fluorothymidine PET predicts response to (V600E) BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med 2013;54:424-30.
33. Haberkorn U, Kinscherf R, Krammer PH, Mier W, Eisenhut M. Investigation of a potential scintigraphic marker of apoptosis: radioiodinated Z-Val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone. Nucl Med Biol 2001;28:793-8.
34. Pereira NA, Song Z. Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity. Biochem Biophys Res Commun 2008;377:873-7.
35. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13:3682-8.
36. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105: 3041-6.
37. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 2010;467:596-9.
38. Rauber P, Angliker H, Walker B, Shaw E. The synthesis of peptidylfluoromethanes and their properties as inhibitors of serine proteinases and cysteine proteinases. Biochem J 1986;239:633-40.
39. Bedner E, Smolewski P, Amstad P, Darzynkiewicz Z. Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): correlation with DNA fragmentation. Exp Cell Res 2000;259:308-13.
40. Amstad PA, Yu G, Johnson GL, Lee BW, Dhawan S, Phelps DJ. Detection of caspase activation in situ by fluorochrome-labeled caspase inhibitors. Biotechniques 2001;31:608-10.
41. Smolewski P, Bedner E, Du L, Hsieh TC, Wu JM, Phelps DJ, et al. Detection of caspases activation by fluorochrome-labeled inhibitors: multiparameter analysis by laser scanning cytometry. Cytometry 2001;44:73-82.
42. Lawson VA, Haigh CL, Roberts B, Kenche VB, Klemm HM, Masters CL, et al. Near-infrared fluorescence imaging of apoptotic neuronal cell death in a live animal model of prion disease. ACS Chem Neurosci 2010;1:720-7.
43. Peterson TE, Manning HC. Molecular imaging: 18F-FDG PET and a whole lot more. J Nucl Med Technol 2009;37:151-61.
44. Eckelman WC, Reba RC, Kelloff GJ. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov Today 2008;13:748-59.
45. Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 2007;50:2213-24.
46. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A 2009;106:16375-80.
47. Chen DL, Zhou D, Chu W, Herrbrich PE, Jones LA, Rothfuss JM, et al. Comparison of radiolabeled isatin analogs for imaging apoptosis with positron emission tomography. Nucl Med Biol 2009; 36:651-8.
48. Chen DL, Zhou D, Chu W, Herrbrich P, Engle JT, Griffin E, et al. Radiolabeled isatin binding to caspase-3 activation induced by anti- Fas antibody. Nucl Med Biol 2012;39:137-44.
49. Su H, Chen G, Gangadharmath U, Gomez LF, Liang Q, Mu F, et al. Evaluation of [(18)F]-CP18 as a PET imaging tracer for apoptosis. Mol Imaging Biol 2013;15:739-47.
50. Xia CF, Chen G, Gangadharmath U, Gomez LF, Liang Q, Mu F, et al. In vitro and in vivo evaluation of the caspase-3 substrate-based radiotracer [(18)F]-CP18 for PET imaging of apoptosis in tumors. Mol Imaging Biol 2013;15:748-57.